Published • loading... • Updated
Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer
- Akeso, Inc. announced the first patient has been enrolled in the Phase III clinical trial for ivonescimab in treating advanced metastatic colorectal cancer.
- This trial is a crucial initiative by Akeso to meet the worldwide unmet clinical need for advanced metastatic colorectal cancer treatment.
- Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related deaths.
- Professor Yanhong Deng presented promising Phase II efficacy data of ivonescimab combined with chemotherapy at the 2024 ESMO Congress.
Insights by Ground AI
54 Articles
54 Articles
Rutland Herald+53 Reposted by 53 other sources
Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer
HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in first-line treatment for…
Coverage Details
Total News Sources54
Leaning Left7Leaning Right4Center33Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
L 16%
C 75%
Factuality
To view factuality data please Upgrade to Premium
